KOL Insight Archives | Page 3 of 8 | Report Store

Non-Alcoholic Steatohepatitis (NASH) Survey

Datamonitor conducted a 4-question survey of 42 United States and 40 European (based in France, Germany, Italy and United Kingdom) gastroenterologists to gauge their views on late-stage clinical candidates in non-alcoholic steatohepatitis (NASH), including Ocaliva (ICPT), elafibranor (GNFTF) and selonsertib (GILD), and their projected use of these drugs if FDA-approved.

KOL Insight

Non-Alcoholic Steatohepatitis (NASH) Survey

Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

Neuromodulation KOL Interview

NASH KOL Insight Interview #2

NASH KOL Insight Interview #1

Multiple Sclerosis KOL Insight Interview

Multiple Sclerosis (MS) KOL Interview – US, Midwest

Multiple Sclerosis (MS) KOL Interview – UK, Southwest

Multiple Sclerosis (MS) KOL Interview – UK, London

Multiple Myeloma KOL Interview – US

Multiple Myeloma KOL Interview – UK

Melanoma KOL Interview – US #2

Melanoma KOL Interview – US #1

MDS/AML KOL Interview

Major Depressive Disorder KOL Interview – UK

Macitenan for Pulmonary Arterial Hypertension

Leukemia KOL Insight and Pulse Survey Bundle

Key Questions in Immuno-Oncology

Intersection Between Tech and Pharma KOL Interview

Inpatient Infections Pulse

Inflammatory Bowel Disease (IBD) KOL Interview – US

Human Papillomavirus (HPV) KOL Interview – US, Midwest

Human Papillomavirus (HPV) KOL Interview – Italy

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #2

HIV Pre-Exposure Prophylaxis (HIV PrEP) KOL Interview – US #1

HER2+ Breast Cancer KOL Interview – US, West Coast

HER2+ Breast Cancer KOL Interview – UK

Hemophilia KOL Interview – US, Southeast

Hemophilia KOL Interview – UK

Head and Neck Cancer KOL Interview – US, Southeast